Milestone presents results from ReVeRA Phase 2 study of Etripamil in AFib-RVR

Milestone Pharmaceuticals announced Phase 2 data that show etripamil nasal spray resulted in rapid and statistically superior ventricular rate reduction and improved symptom-relief in patients with atrial fibrillation with rapid ventricular rate compared to placebo. Safety and tolerability reported in the 56-patient safety population is generally consistent with that observed in Milestone’s much larger Phase 3 paroxysmal supraventricular tachycardia program. The results were presented as a Featured Science presentation at the American Heart Association Scientific Sessions 2023 and simultaneously published in Circulation: Arrhythmia and Electrophysiology. These data support further development of self-administered etripamil for the treatment of AFib-RVR. Serious adverse events occurring in the 24 hours after drug were rare, with two occurring in one patient in the etripamil arm and four occurring in two patients in the placebo arm. The SAEs in the etripamil arm were transient severe bradycardia and syncope, assessed as due to hyper-vagotonia, which occurred in a patient with a history of vagal events, and fully resolved by placing the patient supine and without sequelae.